Albuterol metered dose inhaler performance under... (2009 study) Skip to main content
Study Undersea Hyperb Med 2009

Albuterol metered dose inhaler performance under hyperbaric pressures

Johnson G, Gutti V, Loyalka S, O'Beirne K, Cochran S, Dale H, et al., Undersea Hyperb Med, 2009

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers tested albuterol inhalers inside a hyperbaric chamber at pressures from 1 ATA to 3 ATA to see how much medicine each puff released and how big and how many the aerosol particles were.

What They Found

This laboratory study of albuterol metered dose inhalers (MDIs) found that the amount released per puff and the aerosol particles emitted varied by canister type when the inhalers were used at pressures up to 3 ATA (66 fsw). Weight change per actuation was 13 +/- 1% less for CFC inhalers and 12 +/- 1% less for long canister HFA inhalers at 3 ATA than at 1 ATA, while short canister HFA inhalers showed no significant change. The geometric mean diameter of nanoparticles from the CFC and short canister HFA inhalers fell from 50 nm at 0 fsw to 32 nm at 66 fsw, but long canister HFA particle sizes were not affected. The number of nanometer size particles delivered at 66 fsw was 4-7% of that at 0 fsw for CFC and long canister HFA inhalers, and 26% for short canister inhalers.

What This Means for Canadian Patients

The abstract measured inhaler output in a chamber and did not test patients, so it does not report how well albuterol works for anyone at pressure. It shows that inhaler output changes with pressure and differs by canister type. Anyone who uses an inhaler and is thinking about hyperbaric exposure should ask their care team about it, since the abstract does not give guidance on use.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The abstract describes only measurements of inhaler output in a chamber, with no patients or clinical outcomes reported, so it cannot show whether the changes affect how well the medicine works.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Study
Category Decompression Sickness
Source Pubmed
PubMed ID 19341128
Year Published 2009
Journal Undersea Hyperb Med
MeSH Terms Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchial Spasm; Bronchodilator Agents; Contraindications; Diving; Humans; Hyperbaric Oxygenation; Metered Dose Inhalers; Nanoparticles; Particle Size; Pressure; Weights and Measures

Cite This Study

Share

This study relates to Decompression Sickness. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Decompression Sickness

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology